首页> 外文OA文献 >Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

【2h】

Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

机译：通过合成双官能PD-L1阻断肽增强可切换双嵌合抗原受体工程T细胞的安全性和抗肿瘤效果。通过合成双官能PD-L1阻断肽

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 -1
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide [J] . Peiwei Yang, Ying Wang, Zheng Yao, Journal of the American Chemical Society . 2020,第44期

机译：通过合成双官能PD-L1阻断肽增强可切换双嵌合抗原受体工程T细胞的安全性和抗肿瘤效果。通过合成双官能PD-L1阻断肽
2. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival [J] . Genssler Sabrina, Burger Michael C., Zhang Congcong, Oncoimmunology. . 2016,第4期

机译：嵌合抗原受体工程化的自然杀伤细胞对胶质母细胞瘤的双重靶向克服了靶抗原表达的异质性并增强了抗肿瘤活性和存活率
3. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma [J] . Liu Ying, Di Shengmeng, Shi Bizhi, The Journal of Immunology: Official Journal of the American Association of Immunologists . 2019,第1期

机译：IL-12的铠装型诱导表达增强了肝细胞癌中糖尿病-3靶向嵌合抗原受体工程T细胞的抗肿瘤活性
4. Main Issues and Current Strategies in Enhancing the Efficacy of Chimeric Antigen Receptor T-Cell Therapy among Tumor Treatments [C] . Zhengting He International Conference on Frontiers of Biological Sciences and Engineering . 2020

机译：提高嵌合抗原受体T细胞治疗肿瘤治疗疗效的主要问题及目前策略
5. Optimizing Chimeric Antigen Receptor (CAR) T Cells for an Enhanced and Broadened Anti-Tumor Immune Response Via Il-36γ [D] . Li, Xinghuo. 2020

机译：优化嵌合抗原受体（汽车）T细胞通过IL-36γ进行增强和扩大的抗肿瘤免疫应答
6. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival [O] . Sabrina Genßler, Michael C. Burger, Congcong Zhang, 2016

机译：用嵌合抗原受体工程化的自然杀伤细胞双重靶向胶质母细胞瘤克服了靶抗原表达的异质性并增强了抗肿瘤活性和存活率
7. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity [O] . Congcong Zhang, Pranav Oberoi, Sarah Oelsner, 2017

机译：嵌合抗原受体 - 工程NK-92细胞：用于靶向消除癌细胞和诱导保护性抗肿瘤免疫的现成细胞治疗

Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

著录项

引文网络

相似文献

相关主题

期刊订阅